20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Gainers

• Novavax, Inc. NVAX shares increased by 71.2% to $9.83 during Tuesday's pre-market session.
• Cleveland BioLabs, Inc. CBLI shares increased by 28.0% to $1.37.
• Inovio Pharmaceuticals, Inc. INO stock moved upwards by 22.5% to $4.03. The most recent rating by PiperJaffray, on January 03, is at Overweight, with a price target of $8.00.
• BioCryst Pharmaceuticals, Inc. BCRX shares rose 13.7% to $3.16. According to the most recent rating by Bank of America, on November 15, the current rating is at Buy.
• Bellicum Pharmaceuticals, Inc. BLCM shares moved upwards by 13.5% to $2.60.
• NeuroMetrix, Inc. NURO shares rose 8.7% to $4.63.
• Kamada, Inc. KMDA shares increased by 7.5% to $7.01.
• Aethlon Medical, Inc. AEMD shares surged 7.3% to $2.21.
• OrganiGram Holdings, Inc. OGI shares increased by 6.1% to $3.46. According to the most recent rating by Raymond James, on January 09, the current rating is at Market Perform.
• Galapagos, Inc. GLPG stock increased by 5.1% to $239.23. According to the most recent rating by JP Morgan, on January 06, the current rating is at Neutral.
• Aphria, Inc. APHA shares surged 5.0% to $5.54. According to the most recent rating by CiBC, on January 15, the current rating is at Neutral.
• Cerus, Inc. CERS stock moved upwards by 4.4% to $4.25. According to the most recent rating by BTIG Research, on November 13, the current rating is at Buy.
• Proteostasis Therapeutics, Inc. PTI stock surged 3.1% to $2.02.
• Diffusion Pharmaceuticals, Inc. DFFN shares rose 3.0% to $0.52. The most recent rating by H.C. Wainwright, on December 18, is at Buy, with a price target of $3.50.
• Achieve Life Sciences, Inc. ACHV stock moved upwards by 1.9% to $0.65.
• Titan Pharmaceuticals, Inc. TTNP stock rose 1.8% to $0.34.

Losers

• Tonix Pharmaceuticals, Inc. TNXP stock declined 9.7% to $1.40 during Tuesday's pre-market session.
• Seneca Biopharma, Inc. SNCA shares decreased by 8.1% to $1.47.
• Arrowhead Pharmaceuticals, Inc. ARWR shares fell 7.4% to $52.25. According to the most recent rating by Oppenheimer, on December 13, the current rating is at Perform.
• AstraZeneca, Inc. AZN shares decreased by 2.1% to $50.24. The most recent rating by Cowen & Co., on December 02, is at Outperform, with a price target of $55.00.